Clinical examination about immunoadsorption therapy for dilated cardiomyopathy

Clinical examination about immunoadsorption therapy for dilated cardiomyopathy - Immunoadsorption examination for DCM

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000623

Enrollment

Registered

2007-03-01

Start date

2007-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dilated cardiomyopathy

Interventions

During 10-20 days for study period, 3-5 immunoadsorption therapies will be performed by IMMUSORBA TR (AsahiKasei Medical CO.), which plasma throughput is 2-2.5 liters, three hours per once.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NYHA 3 or 4, Left ventricular ejection fraction less than 30%, more than 6 months of standard medical treatments.

Exclusion criteria

Exclusion criteria: On ACE inhibitors, With known heart basal diseases, Acute myocarditis, Active infectious disease (including viral hepatitis), Neoplasm, Excess alcoholic damages on liver or heart, Pregnancy.

Design outcomes

Primary

Measure	Time frame
Changes of body weight, 6 minutes walking test, cardio-thoracic ratio, echocardiographic parameters, left ventricular ejection fraction, and plasma BNP level after 3-5 immunoadsorption therapies (10-20days).	—

Secondary

Measure	Time frame
Presence of side effect during 3-5 immunoadsorption therapies (10-20days).	—

Countries

Japan

Contacts

Public ContactAkiyasu Baba

Kitasato Institute Hospital Department of Cardiology

web-hospital@kitasato.or.jp03-3444-6161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026